{"id":"W2102195694","doi":"10.1016/s1470-2045(14)70244-x","title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":305,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"University of Arizona Cancer Center; Amgen","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Population; Progression-free survival; Randomized controlled trial; Oncology; Phases of clinical research; Adverse effect; Clinical trial; Surgery; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001289751,0.0003105234,0.0009596377,0.00004540047,0.0002053826,0.00003680605,0.0004333587,0.0002519043,0.000107899],"category_scores_gemma":[0.00007206736,0.0001794519,0.0003528711,0.0001090658,0.0001482236,0.000004859335,0.00005088197,0.0001360709,0.000006673113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005360767,"about_ca_system_score_gemma":0.0002840169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007907247,"about_ca_topic_score_gemma":0.0003852809,"domain_scores_codex":[0.9979805,0.0003652346,0.0004220376,0.0005058191,0.0001527329,0.0005736385],"domain_scores_gemma":[0.998579,0.0002400658,0.0003677287,0.0005489885,0.0001643995,0.00009985683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9531918,0.000518477,0.00006273219,0.00001512384,0.0006385878,0.000001567726,0.0001114641,0.0001052762,0.01239132,0.0002937001,0.00821921,0.02445079],"study_design_scores_gemma":[0.6537257,0.00348529,0.00001682385,0.00001097882,0.0001733057,0.000005508509,0.00002915001,0.0002532259,0.009399851,0.0000174958,0.3326826,0.0002000696],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741189,0.004427747,0.005301976,0.005041062,0.001328086,0.007527007,0.000081823,0.00004259234,0.002130752],"genre_scores_gemma":[0.9815336,0.00287691,0.0007721107,0.002213168,0.006613671,0.004863739,0.00015316,0.00006649876,0.0009070986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3244634,"threshold_uncertainty_score":0.7317837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05990155337821918,"score_gpt":0.3706850085049904,"score_spread":0.3107834551267712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}